Toulouse Cedex 9

• A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in … Ended
  2024-512158-12-00 5 2018-12-14 Bladder Cancer Muscle-Invasive Bladder Cancer
• Cerebral neuroinflammation during major depressive episode: multicentric comparative study (InflaDep) Ended
  2024-518405-18-00 6 2018-12-07 Depressive disorder
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum … Ended
  2023-509061-20-00 9 2018-11-22 Advanced solid tumors
• A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet … Ended
  2023-507312-13-00 5 2018-11-15 Multiple Myeloma
• Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi … Ended
  2024-514179-17-00 5 2018-10-02 Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
• A Study to Evaluate Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lu … Ended
  2023-504038-23-00 9 2018-05-10 Metastatic non-small cell lung cancer (NSCLC)
• A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WI … Ended
  2024-515356-21-00 5 2018-04-17 Adult subject (18 years of age older) with low or intermediate-1 IPSS
• PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStem Ended
  2022-500251-22-00 4 2018-04-12 This study will include all patients having received at least one infu
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of pr … Ended
  2023-510200-42-00 5 2017-12-06 primary sclerosing cholangitis (PSC)
• Perioperative treatment of locally advanced resectable gastric or GEJ adenocarcinoma Ended
  2023-509595-42-00 5 2017-10-31 Gastric and gastroesophageal junction (GEJ) adenocarcinoma
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3 … Ended
  2022-501251-81-00 5 2017-06-08 Renal cell carcinoma
• A study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Risdiplam in adult and pediatric patients with spi … Ended
  2023-506739-14-00 4 2017-05-12 Spinal Muscular Atrophy (SMA)
• A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung … Ended
  2022-501360-18-00 5 2017-03-15 Early Stage Non-Small Cell Lung Cancer (NSCLC)
• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha … Ended
  2024-511967-26-00 5 2016-11-21 AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
• Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended
  2023-507294-18-00 5 2016-09-16 Metastatic renal cell carcinoma
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 5 2016-06-16 Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
• Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG Ended
  2022-502526-41-00 4 2016-03-15 Non-Muscle Invasive Bladder Cancer (NMIBC)
• A Trial to See the Effects of ACP-196 (the test drug) in Patients who have Mantle Cell Lymphoma Ended
  2023-509352-34-00 4 2015-06-18 Mantle Cell Lymphoma
• Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended
  2023-508067-70-00 9 2015-04-15 Neoplasms by site
• BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended
  2024-518931-12-00 4 2014-05-15 Neuroblastoma
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref … Ended
  2023-509472-42-00 5 Relapsed and/or Refractory Multiple Myeloma
• A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease Ended
  2023-510289-28-00 4 Sickle Cell Disease (SCD) and Nephropathy
• A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants … Ended
  2023-510340-20-00 3 Systemic Lupus Erythematosus

Showing 865–888 of 893 trials